The UK government has opted to accept all the recommendations made by its specialist healthcare-focused artificial intelligence (AI) commission around the regulation of AI-enabled medical devices.
This means that British ministers will work to implement all 44 recommendations made by the National Commission into the Regulation of AI in Healthcare, which is advocating for the UK to create an agile regulatory framework with the appropriate guardrails to encourage AI-enabled medical device uptake and innovation as global competition in this space mounts.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In September, the commission led by doctors from the National Health Service (NHS) primarily recommended that – instead of one-time assessments – AI-enabled medical devices are continuously monitored throughout their working life to better ascertain how they perform. The UK government hopes to meet this tenet in the newly introduced third phase of its regulatory sandbox programme, AI Airlock, as it works with device makers, regulators and healthcare partners to determine how best to test and manage post-market surveillance for AI-enabled medical devices.
Meanwhile, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is scheduled to debut draft guidance in December 2026, which will lay out best practices in managing changes to AI-enabled devices as they evolve over time. The regulatory body will also follow another recommendation of the commission by running consultations on how to qualify and classify medical devices incorporating AI.
On top of the MHRA’s efforts, the UK government is also taking active steps to secure the NHS earlier access to AI tools. To achieve this, ministers are currently exploring the potential of new staged authorisation pathways, which could see certain technologies implemented into the public health service with close supervision as researchers collect real-world evidence (RWE) on their utility.
“We want all patients to benefit from the life-saving potential of AI, with the confidence that it is safe, effective and properly overseen,” commented UK health innovation minister, James Frith. “We also want to see the NHS harness the best new technologies to give patients faster, better care and give staff more time to focus on patients. But innovation must never come at the expense of patient safety,” he added.
According to Frith, the UK government’s approach to AI-enabled medical device regulation will continually evolve as the technology develops.
“We are acting now by accepting in full all 44 recommendations of the Independent Commission, which will provide a foundation to embrace the opportunities AI brings while putting strong safeguards, transparency and public confidence at the heart of its use,” Frith said.
AI governance takes centre stage
This comes as regulation in AI is becoming a significant talking point after the Australian government initiated a review into a hacking incident in which tech giant OpenAI’s model secured unintended access to private health files.
Reacting to this, Huntress’ EMEA vCISO and cybersecurity advisor, Muhammad Yahya Patel, raised concerns around the time it took OpenAI to identify the issue.
“If OpenAI’s own monitoring didn’t catch this for two months, how many other environments are currently being accessed by AI agents in ways their developers haven’t intended and don’t yet know about?” Patel questions.
Patel points to the ever-growing importance of airtight governance around AI – particularly in high-risk, regulated contexts such as R&D, where patient safety and privacy may be at risk.
A GlobalData report found that among healthcare providers, pharmaceuticals, and medical devices, the combined AI market was valued at $11.9bn in 2024 and is expected to reach $57.4bn by 2029, representing a compound annual growth rate (CAGR) of about 37%.
